| Literature DB >> 31218190 |
Takuya Oyakawa1, Hiroyuki Fukuda2, Nao Muraoka1, Kei Iida1, Masatoshi Kusuhara3.
Abstract
The effect of direct oral anticoagulants (DOACs) on cancer-associated cerebral infarction (CI) is unclear. We present the clinical course of 20 consecutive patients with cancer-associated CI that developed during treatment with DOACs. The incidence rate of cancer-associated CI during the treatment with DOACs was 3.4%. The median modified Rankin scale (mRS) and Karnofsky performance status (KPS) after CI were 5 and 30, respectively. The median survival time after CI was 1 month. In the group in which the thrombus due to venous thromboembolism (VTE) was reduced before CI, the median mRS, KPS, and prognosis after CI were significantly better than in those of the group with unchanged thrombus. Cancer-associated CI also developed in patients taking DOACs and those who did not show VTE recurrence. When the VTE thrombus decreased or disappeared with DOAC treatment, the clinical course after cancer-associated CI was improved.Entities:
Keywords: Cancer-associated thrombosis; Cardio-oncology; Cerebral infarction; Direct oral anti-coagulant; Venous thromboembolism
Year: 2019 PMID： 31218190 PMCID： PMC6545186 DOI： 10.1007/s13691-019-00370-w
Source DB: PubMed Journal: Int Cancer Conf J ISSN： 2192-3183